 CAMBRIDGE, Mass., June 22, 2021 GLOBE NEWSWIRE -- Agios Pharmaceuticals, Inc. NASDAQ: AGIO, a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced the launch of myAgios patient support services for people living with pyruvate kinase PK deficiency and their caregivers. After enrolling in the program, patients and caregivers will be connected with a dedicated Patient Support Manager PSM with a clinical background to provide tailored support, educational resources and opportunities to connect with other patients and caregivers in the community. 